MediWound and Vericel up on U.S. availability of their burn medication

Vericel

21/09/2023 16:22

** U.S.-listed shares of Israel-based drug maker MediWound  
 MDWD.O  rise 2.1% to $9.24
    ** Shares of Vericel  VCEL.O  also up 3% at $33.50
    ** Says cos' topical medication NexoBrid is now commercially
available in the U.S 
    ** NexoBrid is used for the removal of dead tissue in adults
with deep thermal burns
    ** Including session moves, VCEL up 28.2% and MDWD down
31.5% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))